Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
82 hedge funds and large institutions have $66M invested in Kezar Life Sciences in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 28 closing their positions.
22% more call options, than puts
Call options by funds: $866K | Put options by funds: $709K
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.22% less ownership
Funds ownership: 78.55% → 76.33% (-2.2%)
21% less funds holding
Funds holding: 104 → 82 (-22)
53% less capital invested
Capital invested by funds: $139M → $66M (-$73.4M)
79% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$1.25M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$946K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$578K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$283K |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$274K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$791K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$710K |
| 3 |
Morgan Stanley
New York
|
-$632K |
| 4 |
Millennium Management
New York
|
-$601K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$590K |
KZR Hedge Fund Activity: Q3 2023 in Review
82 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2023, worth a combined $66M — down 53% from $139M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KZR and 6 opened new positions — a net loss of 22 holders — while 32 trimmed existing stakes and 35 added.
The largest buyer was International Biotechnology Trust, opening a new position worth an estimated $1.25M. The largest seller was Granahan Investment Management, cutting an estimated $791K.
- 82 institutional investors held Kezar Life Sciences (KZR) as of Q3 2023, down from 104 in Q2 2023.
- Funds reported $66M of Kezar Life Sciences stock for Q3 2023, down 53% quarter-over-quarter.
- 6 funds opened new Kezar Life Sciences positions in Q3 2023 and 28 closed out, a net change of -22 holders.
- The largest Kezar Life Sciences buyer in Q3 2023 was International Biotechnology Trust, an estimated $1.25M added.
- The largest Kezar Life Sciences seller in Q3 2023 was Granahan Investment Management, an estimated $791K sold.
Based on aggregated 13F filings for Q3 2023.